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Management of nodal diffuse large B-cell lymphomas:
practice guidelines from the Italian Society of
Hematology, the Italian Society of Experimental
Hematology and the Italian Group for Bone Marrow
Transplantation 
The annual incidence of large B-celllymphoma (DLBCL) is 2-8 cases per100,000 inhabitants per year.1 This
disease accounts for 20 to 40 % of cases of
non-Hodgkin’s lymphoma (NHL),1-3 and the
median overall survival (OS) of patients
with DLBCL is shorter than 5 years.4 Several
therapeutic innovations have been recently
introduced, and subjective integration of
older and new pieces of evidence may lead
to conflicting conclusions and a large varia-
tion in clinical practice. In order to select the
best available treatments, avoiding inappro-
priate ones, the Italian Society of Hema-
tology (SIE), the Italian Society of
Experimental Hematology (SIES) and the
Italian Group for Bone Marrow Trans-
plantation (GITMO) supported the develop-
ment of clinical practice guidelines focusing
on the therapy of nodal DLBCL. The guide-
lines are intended to help hematologists,
oncologists and internists who care for
patients with lymphoma.
Design and Methods
Organization and design
The organization and design of this proj-
ect have been reported in a previous paper
on guidelines for the management of nodal
indolent non-Hodgkin lymphomas.5 The
first search of evidence databases was per-
formed on 20th July 2003, but updated
searches of the literature were continued
during the project. The full reference list
(including the abstracts of full papers) is
available on request from marchettim@smat-
teo.pv.it. The grading system chosen for the
present guidelines is the one developed by
the Scottish Intercollegiate Guideline
Network (SIGN).6 The recommendations
are, therefore, graded class A if supported by
consistent and applicable level 1 evidence (at
least one level 1++ trial or some consistent
level 1+ trials), class B if evidence was
derived from consistent results of level 2++
studies or was extrapolated from level
1+/1++ trials, class C if supported by grade
2+ studies that could be applied directly to
the object population and provided consis-
tent results, or level 1++ studies from differ-
ent populations (translated evidence), and
grade D when supported by poor quality
evidence or evidence extrapolated from
grade 2+ studies, and thus sustained mainly
by experts’ opinion. The draft guidelines
were reviewed by an external Panel of
expert radiotherapists and by the presidents
of the SIE, SIES and GITMO scientific soci-
eties. Updating of the present guidelines is
expected in 2008.
Definitions
During the first consensus conference, the
Expert Panel (EP) agreed to address DLBCL,
defined according to the WHO classification
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missioned a project to develop clinical practice guidelines for the treatment of nodal diffuse
large B-cell non Hodgkin lymphomas (DLBCL). Key questions clinically relevant to the man-
agement of patients with nodal DLBCL were formulated by an Advisory Committee (AC) and
approved by an Expert Panel (EP) composed of eight senior hematologists. After a compre-
hensive and systematic literature review, the EP formulated therapy recommendations and
graded them according to the supporting evidence. An explicit approach to consensus
methodologies was used for evidence interpretation and for producing recommendations in
the absence of strong evidence. The EP formulated recommendations on which first-line
therapy to choose in patients with nodal DLBCL. Patients of all ages, with stage I-II disease
and no adverse prognostic factors should receive abbreviated chemotherapy with an
anthracycline-containing regimen plus involved field radiotherapy (35-40 Gy). Patients with
stage I-II disease and at least one adverse prognostic factor, or with stage III-IV disease,
should receive frontline chemoimmunotherapy with CHOP, CHOP-like or third-generation
chemotherapy plus rituximab. Recommendations on stem cell transplantation and on which
therapy to adopt for refractory or relapsed patients were also formulated.
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of mature peripheral B-cell neoplasms, excluding pri-
marily mediastinal lymphomas. HIV-related lym-
phomas and Richter’s syndrome were excluded from
the target domain of the present guidelines. The EP also
agreed on the use of the Ann Arbor staging system as
modified by the Cotswolds meeting,7 and on the use of
the International Prognostic Index (IPI).8 Standard defi-
nitions for response were adopted (Table 1).9 An opera-
tional definition of elderly patients was considered that
takes into account not only age but also performance
status and comorbidities of the patients.
Results
First-line therapy for stage I-II disease
The EP addressed two main issues concerning the
optimal therapeutic strategy for localized DLBCL:
should patients receive radiotherapy (RT), and should
young patients receive more aggressive chemotherapy
than the standard CHOP regimen? Evidence on the
efficacy of, extended field RT derived from a detailed
retrospective analysis.10 of 451 adult patients (243 with
histological high-grade disease) initially treated with
RT alone; the complete remission (CR) rate was 84%.
In those patients under 60 years of age at diagnosis, the
overall cause-specific survival at 10 years was 80%.
Evidence on greater efficacy of RT plus chemotherapy
with respect to RT alone was derived from one ran-
domized trial (level 1+).11 From 1974 to 1978, 73
patients were treated with RT alone or RT plus adju-
vant chemotherapy with vincristine, streptonigrin,
cyclophosphamide and prednisone. With a median fol-
low-up of 5 years, 54% of patients in the RT group had
relapsed versus only 10% in the RT plus chemotherapy
group (p<0.01). There was no statistical difference in
the OS, but 13/14 deaths in the radiotherapy group ver-
sus only 3/12 in the radiotherapy plus chemotherapy
group were due to progressive disease. Evidence on the
greater efficacy of chemoradiotherapy with respect to
chemotherapy alone was derived from two random-
ized trials.12,13. The SWOG study enrolled patients with
intermediate or high grade NHL. Two hundred patients
were randomly assigned to receive three courses of
CHOP plus radiotherapy or CHOP alone.12 Patients
treated with chemoradiotherapy had significantly bet-
ter progression-free survival (PFS) (p=0.03) and OS
(p=0.02) than had patients treated with chemotherapy
alone. The 5-year estimates of PFS and OS for patients
receiving chemotherapy plus RT and for patients
receiving chemotherapy alone were 77% and 64%,
respectively, and 82% and 72%, respectively. Life-
threatening toxic effects of any type were seen in 61 of
200 patients treated with CHOP plus RT and in 80 of
201 patients treated with CHOP alone (p=0.06). From
1984 to 1992, an ECOG study enrolled adult patients
with stage I and II diffuse aggressive lymphoma in
complete remission after eight cycles of CHOP.13
Patients were randomly assigned to 30 Gy involved-
field RT or observation. Among 172 complete remis-
sion patients, the 6-year disease-free survival (DFS) was
73% in the low-dose RT group versus 56% in the group
assigned to observation (p=0.05). Failure-free survival
(FFS) and time to progression (TTP) were also margin-
ally better in the RT group, although no survival bene-
fit was observed. Moreover, only 43% of the 399
patients initially registered actually received RT or
observation. In the long term analysis of the SWOG
trial, PFS and OS of chemo-radiotherapy and
chemotherapy overlapped,14 and in the as-treatment
analysis of the ECOG trial, the survival benefit provid-
ed by chemo-radiotherapy was no longer statistically
significant. The results of the two above mentioned
randomized trials were confirmed by observational
non-controlled studies documenting that an abbreviat-
ed course of doxorubicin-based chemotherapy associ-
ated with RT limited hematologic and cardiac toxicities
and drop-outs, while achieving an OS of more than
Table 1. Response criteria for lymphomas. 
Response Category Lymph Nodes Other sites Bone Marrow
Complete Response (CR) Regression to ≤1.5cm GTD in nodes >1.5 cm Regression or maintenance Normal
before therapy and to ≤ 1 cm GTD (or by more of 75% SPD) of normal size
in nodes 1.1-1.5 cm before therapy 
Complete Response Possible residual nodes >1.5 cm GTD but Regression or maintenance Normal or indeterminate
undefined (CRu) with a SPD regression by >75% of normal size (increased number or size of 
aggregates without cytological
or architectural atypia)
Partial Response (PR) >50% decrease in SPD of the 6 largest nodes or nodal Spleen and liver: no increase in size; Irrelevant 
masses and no increase in size of other nodes regression by >50% in nodules.
No new sites of disease.
Relapse Appearance of any new nodes and/or increase by Appearance of any new lesion and/or Appearance or reappearance 
(for patients with CR >50% in the size of previously involved nodes increase by ≥50% in the size of involvement
or Cru at the end of previously involved sites
of therapy)
Progression >50% increase from nadir in SPD Appearance of any new lesion Appearance or reappearance 
(for patients on therapy of any previously abnormal node of involvement
or with PR or nonresponders 
at the end of therapy)
GTD: greatest transverse diameter; SPD: sum of the products of the greatest diameter (adapted from: Cheson et al.).9
60% and a PFS of more than 70% at 10 years (level 2-
/2++). Nevertheless, the need for RT has been ques-
tioned by two randomized trials by the GELA group;
one trial was in young individuals, the other in elderly
patients.15,16 In the first one, it was found that younger
patients with low-risk localized lymphoma had a
longer survival after dose-dense chemotherapy fol-
lowed by consolidation chemotherapy, as compared
with chemo-radiotherapy. In the second trial, 528 eld-
erly patients with localized good prognosis (IPI 0)
aggressive lymphoma were randomized to receive four
courses of CHOP alone, or the same regimen followed
by 40 Gy involved field (IF)RT. With a median follow-
up of 49 months, chemotherapy alone was as effective
as the combined treatment: the 5-year EFS and 5-year
OS were 66% and 76% with CHOP alone as compared
to 61% and 67%, respectively, for CHOP plus involved
field RT. In patients over 69 years old, OS was better in
those who were not given RT. 
The EP discussed that most of the differences among
studies could have resulted from different inclusion cri-
teria and broad application of the term limited or local-
ized for early stage disease. The EP concluded that the
IPI score allows identification of patients with different
prognoses also among those with stage I and II aggres-
sive lymphomas, and patients with very limited disease
(IPI score =0) have a good prognosis with a 10-year OS
from 87% to 95% whether they are treated with an
abbreviated course of doxorubicin-based chemothera-
py followed by RT or with chemotherapy alone.
Although dose-dense chemotherapy was shown to be
effective in these patients and the number of fatal sec-
ond cancers in the two group of the GELA trial was not
significantly different, the EP deemed that the risk of
toxicity due to dose-dense chemotherapy needs to be
accurately balanced against the potential benefits.
Therefore, the EP judged that dose-dense chemothera-
py could not be recommended in very limited stages of
aggressive NHL.
Recommendations
Patients of all ages with stage I-II DLBCL and no adverse
prognostic factors, i.e. non-bulky disease and IPI prognostic
index equal to 0 (normal LDH serum levels, ECOG perform-
ance status < 2) should receive abbreviated chemotherapy
with an anthracycline-containing regimen plus involved field
RT (35-40 Gy) or a full course of chemotherapy alone [grade
C]. Patients with stage I-II disease and at least one adverse
prognostic factor (bulky disease, elevated LDH, performance
status ECOG >1) should be treated according to the recom-
mendations for stage III-IV disease [grade D]. 
First-line therapy for stage III-IV disease
A randomized trial conducted in elderly patients (60-
69 years) with poor-prognosis aggressive non-Hodgkin’s
lymphoma showed that increased anthracycline and
cyclophosphamide doses with interval reduction
(ACVBP regimen) produced better 5-year EFS rates and
OS than did standard CHOP chemotherapy.17 A dose-
finding study,18 and two randomized studies19,20 tested
the superiority of 2-weekly or 3-weekly CHOP
chemotherapy with or without etoposide for patients
with aggressive lymphomas. In patients aged 61 to 75
years complete remission rates were 60.1% (CHOP-21),
70.0% (CHOEP-21), 76.1% (CHOP-14), and 71.6%
(CHOEP-14). Five-year EFS rates and OS rates were
32.5% and 40.6%, respectively, for CHOP-21 and
43.8% and 53.3%, respectively, for CHOP-14. These
studies provided evidence that CHOEP should be the
preferred chemotherapy regimen for young patients
with good-prognosis aggressive lymphoma, while due
to its favorable efficacy and toxicity profile, CHOP-14
should be considered for patients aged 60 or older.
Evidence that the association of chemotherapy and rit-
uximab, i.e. chemoimmunotherapy, improved OS
derived from one randomized trial.21 In older patients,
the GELA NHL 98.5 randomized trial (level 1++)
showed that the administration of rituximab, 375
mg/m2 on day 1 of each cycle alongside standard CHOP
chemotherapy (R-CHOP), i.e. 8 cycles every 21 days,
reduced the risk of death by 36% and increased 2-year
OS by 19% compared to CHOP alone. R-CHOP signif-
icantly improved EFS rates in both low and high risk
patients and in bcl-2-positive patients, potentially over-
coming the impact of this negative prognostic factor.22
These results were recently confirmed in un updated
report with a 5-year median follow-up.23 The EP was
quite confident that the efficacy of chemoimmunother-
apy is preserved in patients over 80 years of age who are
eligible chemotherapy, since rituximab did not increase
the overall toxicity of treatment. The efficacy of
chemoimmunotherapy in both elderly and young
patients has been recently confirmed by a large popula-
tion-based prospective study (level 2++).24 By compar-
ing patients’ survival before and after rituximab intro-
duction into clinical practice, the British Columbia
Cancer Agency observed that 2-year OS improved
from 53% to 77% (p=0.0001) and 2-year PFS increased
from 52% to 71%. In the elderly (>60 yrs) OS improved
from 40% to 67% and PFS from 44% to 67%. In the
young, OS improved from 69% to 87% and PFS
increased by 10% (p=n.s.). Indeed, no difference in out-
comes between young and old patients receiving
chemoimmunotherapy was detected in a phase II
study.25 Evidence of the efficacy of chemoimmunother-
apy in patients younger than 60 years was also derived
from a partially reported randomized trial: the
MabThera International Trial enrolled 820 patients
aged less than 60 years and with an IPI score 0-1 (low
risk) and administered rituximab every 21 days irre-
spective of chemotherapy scheduling, which included
third-generation chemotherapy regimens, CHOP and
CHOP-like chemotherapy.26 However, direct evidence
of the benefit of chemoimmunotherapy in young
patients at high risk (IPI score 2-3) is still lacking. 
The evidence on the use of rituximab as a single agent
was translated from data on rituximab monotherapy in
relapsed patients. The drug, administered at the dose of
375 mg/m2 weekly for 4 weeks produced responses
(mostly partial responses) in 30-40% of the patients in
this setting. Maintenance rituximab after first-line
chemoimmunotherapy is still under investigation. The
EP judged that evidence was too scarce to recommend
rituximab as a maintenance regimen. 
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High-dose chemotherapy with autologous stem cell
rescue (HDT/autoSCT) was expected to improve
chemotherapy outcomes in high-risk DLBCL patients.
Indeed, in some clinical trials the survival curve after
early HDT/autoSCT (i.e. first CR) proved superior to
that after conventional chemotherapy, indicating the
potential of this treatment to eradicate the disease.
These observations are in contrast with those of two
meta-analyses (level 1+) of up to 11 randomized tri-
als,27,28 which showed a similar OS in patients receiving
first-line HDT/autoSCT or standard chemotherapy.
The significant heterogeneity among the studies, due to
different study designs and treatment strategies, how-
ever, made the meta-analytic process itself poorly
robust. Indeed, the studies in which the HDT/autoSCT
arm had fewer than 25% drop-outs provided a signifi-
cant reduction of mortality (OR 0.44, p=0.01). Some
studies employing upfront high-dose sequential
chemotherapy (HDS) reported a significant improve-
ment in OS. However, in a recent trial by the
Intergruppo Italiano Linfomi, this strategy did not
improve the outcome in IPI 2-3 patients compared to
dose-dense chemotherapy.29 The EP judged that the evi-
dence supporting the superiority of HDT/autoSCT over
conventional chemotherapy is still too scarce and het-
erogeneous for a universal recommendation of first-line
HDT/autoSCT. Moreover, chemoimmunotherapy
greatly improved the long-term outcomes of patients
with DLBCL and ongoing randomized studies are com-
paring chemoimmunotherapy with HDT/autoSCT in
first-line therapy for DLBCL. The EP therefore recom-
mended that non-elderly, high-risk patients may be
selected for a frontline HDT/autoSCT strategy accord-
ing to approved clinical protocols. The EP deemed it
advisable that full debulking should precede HDT/SCT,
since shortened induction is probably associated with
worse outcomes after HDT/SCT.23
An old randomized study prospectively compared
involved field RT consolidation with no consolidation
in 155 patients with a CR after CHOP-bleomycin
chemotherapy (level 1-).30 Involved field RT increased 5-
year PFS from 35% to 72% and OS from 55% to 81%.
These results were confirmed by non-randomized
prospective (level 2+) and retrospective (level 2-) stud-
ies. RT doses ranged from 30 Gy to 53 Gy in the vari-
ous studies, and was 45 Gy in the randomized study.30
However, the EP judged it worth recommending a
lower RT dose, in order to limit long-term occurrence of
secondary cancers, being confident that the efficacy of
consolidation involved field RT was preserved also at
the 30-36 Gy dose. However, no well designed ran-
domized studies properly addressed the issue of consol-
idation RT in advanced disease. Large co-operative
groups, such as GELA, have been avoiding RT in their
randomized trials for the past years in patients in CR
with no evidence of inferior results.31 In the German
studies, involved field RT (36 Gy) was delivered to the
areas of intial bulky disease (>7.5 cm), irrespective of
the results of chemotherapy.19,20 The interest in avoiding
RT is to spare long-term toxicity such as cardiac or sec-
ondary malignancies in these patients. It has recently
been shown that a persistent positive positron electron
tomography (PET) scan after front-line chemotherapy
had a very poor prognostic impact on OS in patients
with aggressive lymphoma. PET proved to have a high
sensitivity and specificity for residual lymphoma mass-
es and it might be argued that RT could be modulated
based on the results of PET scans after chemotherapy.
However, specific, randomized studies should be
focused on this issue. 
The risk of central nervous system (CNS) relapse in
patients with intermediate-high grade NHL is about
5%, but a high-intermediate/high IPI score predicted a
higher risk of CNS relapse. Chemoimmunotherapy did
not reduce the risk of CNS relapses as compared with
chemotherapy alone in a retrospective study.32 There-
fore, the EP deemed it worth formulating a risk-adjust-
ed recommendation for CNS prophylaxis in this subset
of patients. Prophylaxis of CNS relapse should be given
to patients with involvement of specific extranodal sites
such as the testes, paranasal sinuses, hard palate, orbit,
paravertebral masses and bone marrow. Patients with a
high-intermediate/high IPI score, particularly reflecting
the presence of a high level of LDH and involvement of
more than one extranodal site,33 are at much higher risk
of CNS involvement than other patients and intrathecal
prophylaxis should be suggested. 
Recommendations
Patients with stage III-IV disease should receive frontline
chemoimmunotherapy with CHOP, CHOP-like or third-gen-
eration chemotherapy plus rituximab [grade A/B]. The use of
rituximab as first-line monotherapy is not recommended,
except for patients with stage III-IV disease who are, tem-
porarily or definitely, ineligible for chemotherapy [grade C].
Patients with an intermediate-high/high IPI score and who are
less than 65 years old may receive a frontline HDT/autoSCT,
but only within an approved study protocol. Patients enrolled
into an HDT/autoSCT program should receive non-abbrevi-
ated debulking treatment [grade B]. 
Frontline allogeneic SCT is not recommended for any patient
[grade C]. 
Patients with stage III-IV disease and bulky disease at
diagnosis may receive consolidation involved field RT (30-36
Gy) to the sites of bulky disease [grade C]. 
Prophylaxis of CNS relapse should be performed in patients
with involvement of specific extranodal sites such as the testes,
paranasal sinuses, hard palate, orbit, paravertebral masses and
bone marrow [grade B]. 
Prophylaxis of CNS relapse should also be used in patients
presenting with a high-intermediate /high IPI score, particular-
ly reflecting the presence of a high level of LDH and involvement
of more than one extranodal site [grade C]. Prophylaxis should
be performed with intrathecal injections of methotrexate at the
beginning of each cycle of chemotherapy. The first intrathecal
treatments should be administered within 14 days after the start
of chemotherapy. 
There is no role for maintenance therapy in patients in com-
plete remission after first-line therapy outside a clinical trial.
Restaging and monitoring 
PET has proven to have a high sensitivity and speci-
ficity for the detection of residual lymphoma masses
and its diagnostic yield is greatly increased by associa-
Management guidelines for nodal diffuse DLBCL
haematologica/the hematology journal | 2006; 91(1) | 99 |
tion with computed tomography scans. A longer PFS
and lower relapse rate were found in PET-negative
patients. Relapse rates ranged from 62.5% to 100% in
PET-positive patients and from 3% to 17% in PET-neg-
ative ones.34,35 Preliminary data indicate that PET also
has a better diagnostic yield over magnetic resonance
imaging.36 The EP considered the evidence of the diag-
nostic and prognostic role of PET in restaging DLBCL
was consistent and recommended this test. PET scan-
ning has a positive predictive value of 89% and a nega-
tive predictive value of 62% in assessing bone marrow
involvement,37 therefore, a negative PET scan is not
considered sufficient for restaging patients with bone
marrow involvement at diagnosis. Due to the heteroge-
neous populations enrolled into the studies assessing
PET, including Hodgkin's lymphoma and NHL patients,
the evidence supporting the prognostic yield of PET
was down-scored to levels II and III.
Recommendations
Within 2 months after the end of first-line therapy (more than
3 months after completion of radiotherapy), patients with
DLBCL should be restaged with CT and PET scans independ-
ently of the presence of a site of bulky disease at the time of
diagnosis [grade D]. Bone marrow biopsy should be also per-
formed in patients with bone marrow involvement at diagnosis
[grade A]. 
All the patients with a CR-undefined and gastric, liver or
intestinal involvement at diagnosis should have specific biopsies
repeated if the surgical procedure is not severely harmful to the
patient [grade B]. 
Patients with a complete remission should receive monitoring
follow-up visits starting 3 months after restaging and repeated
every 3 months for the first 24 months, then every 6 months for
36 months [grade D].
Second-line therapy
Before planning appropriate therapy, relapsed
patients need to be adequately restaged. 
Non-cross-reacting chemotherapy regimens, such as
DHAP, ICE, MIME and high-dose regimens, such as
HDS, proved to be effective in this subset of patients.38,39
Evidence on the efficacy of adding rituximab to rein-
duction chemotherapy was derived from non-con-
trolled trials. Since prior administration of rituximab
might impair CD20 expression on the surface of malig-
nant cells, and since rituximab therapy requires CD20
expression by target cells for its efficacy, the EP recom-
mended that the expression of this antigen should be
assessed before including rituximab in any reinduction
therapy.
After reinduction with non-cross-resistant chemo-
therapy, chemosensitive patients aged less than 65
years old who were free of severe comorbidity
achieved a 5-years EFS of 35-60% after high-dose ther-
apy and HDT/autoSCT, depending on prognostic fac-
tors at relapse (level 1++).40 These data were confirmed
by the ABMT registry (level 2++)41 and other longitudi-
nal studies (level 2+). A pooled analysis of three phase
II studies (level 2++)42 showed that the age-adjusted IPI
score predicted outcome (logrank p=0.001) after
HDT/autoSCT in this clinical setting: 150 refractory or
relapsed patients received ICE followed by the  HDT/
autoSCT program. Patients with primary refractory dis-
ease had a 4-year OS of 27% and a 4-year PFS of 20%,
however, those who responded to ICE had a similar
outcome as chemosensitive, relapsed patients. 
High-dose chemotherapy followed by the HDT
/autoSCT is also feasible in older patients, however, evi-
dence is still scanty and the EP deemed it insufficient to
formulate a specific recommendation; this strategy
requires further investigation in controlled clinical studies.
The effect of in vivo purging on mobilization yield,
time of engraftment and immune reconstitution in
patients receiving in vivo purging is still being investigat-
ed. Rituximab cannot be recommended for mainte-
nance after HDT/autoSCT, since no improvement in
EFS was reported at 13 months of follow-up by the
ongoing LNH 98-B3 GELA randomized trial.43 Involved
field RT to sites of bulky disease may be a useful con-
solidation therapy after HDT/autoSCT. Tandem
HDT/autoSCT has been proposed as part of the initial
therapy for DLBCL, however evidence is still scanty
and non-comparative. 
Patients who are not eligible for HDT/autoSCT may
receive clinical benefit from radioimmunoconjugates
(RIT) based on translated evidence from phase II stud-
ies including small subgroups of patients with aggres-
sive NHL. The EP suggested that RIT should adminis-
tered in the context of approved clinical protocols.
Patients who slowly achieve response to first-line
therapy have a prognosis similar to that of patients
with a PR, however, validation of this dynamic factor
or incorporation into official response evaluation sys-
tems has not been judged consistent, yet. Therefore,
the EP deemed it not to be appropriate to recommend
different routine second-line therapies according to the
response kinetics. Patients with IPI 2-3 and/or an early
relapse (within 12 months) have a higher risk of relapse
after HDT/SCT. Therefore, alternative experimental
therapies may be offered to this subset of patients. 
Relapsed patients who are not eligible for autoSCT
and who are younger than 65 years can be considered
for allogeneic stem cell transplantation (allo-SCT). Allo-
SCT has been demonstrated to cure DLBCL in most of
the patients who survive after the procedure: both
relapse and survival curves reach a plateau 12-24
months after transplantation. However, the 5-year OS
was reported to be 20-30% in refractory/relapsed
DLBCL patients and no survival advantage was found
between allo and autoSCT in a retrospective analysis of
high-grade and DLBCL patients.
Recently, some evidence suggested that it may be
possible to use the graft-versus-lymphoma (GVL) effect
as a therapy for DLBCL without the need for myeloab-
lative therapy, i.e. using reduced-intensity conditioning
(RICT). Replacing high dose myeloablative therapy
with a non-myeloablative conditioning regimen would
allow treatment of those patients who are too old or
medically unfit to qualify for conventional allografting.
RICT has markedly reduced transplant-related mortali-
ty (TRM) (level 2).44 However, TRM is still a main limi-
tation to the use of allo-SCT and age remains a major
determinant of TRM since patients over 50 years show
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a 2-fold higher TRM even after RICT (level 2++ trans-
lated).45 The potential benefits of RICT in patients with
aggressive NHL were evaluated in 19 patients who
received a low-intensity fludarabine-based condition-
ing regimen for allografting.45 All patients engrafted.
Transplant-related toxicity was moderate and four
patients developed GVHD. At 37 months 40% of
patients were disease-free. A recent review of the
EBMT experience in 188 patients with lymphoma
treated with RICT was less encouraging. Those
patients with high-grade NHL had a poor outcome and
the authors concluded that RICT may not be appropri-
ate for DLBCL. Very promising results have recently
been reported from two phase II studies with RICT in
patients with various subtypes of NHL relapsing after
auto-SCT. Extended use of allo-SCT in cases with little
chance of disease control with auto SCT may be pre-
dicted from these reports.
Recommendations
Patients without a complete remission after first-line therapy
and who are under 65 years old should receive non-cross-
resistant regimens (e.g. ICE, DHAP, MIME, HDS) with or
without rituximab [grade B]. Patients with a good performance
status showing chemosensitivity to rescue chemotherapy should
proceed to high-dose chemotherapy with HDT/SCT [grade A].
Patients chemoresistant to rescue chemotherapy should be
enrolled into approved study protocols testing new drugs or
experimental therapies (e.g. radioimmunoconjugates) or allo-
geneic SCT or receive supportive therapy [grade C]. 
Patients who do not achieve a complete remission after first-
line therapy but aged more than 65 years should receive
radioimmunoconjugates or non-cross resistant chemotherapy. 
Patients with a disease relapse need to be restaged and
CD20 positivity should be assessed before prescribing ritux-
imab-containing therapy [grade D]. 
At first relapse, patients need to receive non-cross-resistant
chemotherapy regimens (i.e. ICE, DHAP, MIME, HDS), with
or without rituximab followed, in eligible patients, by high-dose
chemotherapy and HDT/SCT [grade B]. Patients eligible for
HDT/SCT include those aged < 65 years, with chemosensitive
disease and a good performance status, without comorbidities
and with good availability of autologous stem cells [grade A].
Eligible patients with an early relapse (<6 months from the end
of first-line therapy) or an age-adjusted IPI score of 2-3 at the
time of relapse are at high risk of relapse after HDT/SCT. The
Panel advise enrollment of these patients into approved study
protocols with experimental therapies [grade B]. 
Patients who are not eligible for HDT/SCT should be
enrolled into approved study protocols of investigational thera-
pies (e.g. radioimmunoconjugates, allogeneic SCT) or receive
supportive therapy. 
Mobilized peripheral blood stem cells should be preferred to
bone marrow stem cells for HDT/SCT. Several procedures are
available for mobilization of autologous stem cells: the combi-
nation of chemotherapy and granulocyte colony-stimulating
factor may be preferred since this produces higher yields of pro-
genitor cells than does the cytokine alone [grade C]. No data
are available to support the use of ex-vivo purging for
HDT/SCT and data reported so far are not sufficient to recom-
mend the use of rituximab in vivo purging in all patients under-
going HDT/SCT. There are insufficient data to recommend the
use of double autologous transplantation. There are insufficient
data to recommend the use of maintenance therapy after
HDT/SCT. 
Younger patients (< 50 years) who are candidates for allo-
geneic SCT should receive myeloablative conditioning. Patients
aged over 50 years old should receive reduced-intensity condi-
tioning [grade D]. 
Stem cells from either a sibling or an unrelated donor can be
employed for allogeneic SCT [grade D]. The Panel suggested
that total body irradiation may be incorporated into the condi-
tioning regimen for myeloablative allogeneic SCT [grade D].
Fludarabine-containing conditioning regimens should be
employed for reduced-intensity allogeneic SCT [grade C]. 
All patients with a bulky mass should receive involved field
radiotherapy (30-36 Gy) to bulky sites after chemotherapy and
high-dose therapy [grade B].
Discussion
In order to meet physicians’ needs, the present guide-
lines are focused on the most relevant and specific issues
in the complex clinical management of DLBCL. An
extensive and systematic review of literature provided
an up-to-date evidence base. However, in order to
adhere to the quality standards for guideline produc-
tion,46 the SIES, SIE nd GITMO initiative of producing
practice guidelines comprised interpretation and consen-
sus on the evidence by members of an EP and a consen-
sus phase for recommendations on key clinical issues not
supported by good evidence. 
Within this conceptual framework, the results of this
project mostly adhered to the quality items produced by
AGREE.47 The only exceptions are that patients’ views
and preferences were seldom explicitly formulated into
the recommendations, a pilot application of the guide-
lines has not been attempted and a monitoring or audit
process has not been initiated. However, these guide-
lines have been externally reviewed by three expert
radiotherapists and three senior hematologists, i.e. the
presidents of the scientific societies endorsing the pres-
ent guidelines. 
The present guidelines are also aimed at supporting a
rational use of novel technologies still under evaluation,
such as monoclonal antibodies, reduced intensity condi-
tioning and stem cell transplantation. The guidelines
therefore cover a large domain, including the decision on
how to approach first-line therapy, and the treatment of
refractory and relapsed patients. Furthermore, different
recommendations were formulated for diverse clinical
scenarios, making the recommendations patient-specific.
However, neither supportive therapy, i.e. hematopoietic
growth factors, nor therapies for lymphoma-related
complications, i.e. drugs for lymphoma-related autoim-
mune disorders, were specifically addressed by the pres-
ent guidelines, since these issues belong to more general
supportive care in the field of hemato-oncology.
Recommendations on the prevention of tumor lysis syn-
drome were also left out of by the present guidelines
because they are not specific to DLBCL. The present
guidelines agree with all other guidelines on the recom-
mendation for first-line chemoimmunotherapy for elder-
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ly patients (Table 2).48-52 Conversely, the strength of the
recommendation for the use of rituximab differs among
the guidelines, being quite low in the position paper by
the Cancer Care Ontario Network.48 This may be partial-
ly related to the different updating times of the guide-
lines. The present guidelines also agree with NCCN
guidelines on the treatment of relapsed/refractory
patients, while heterogeneous recommendations were
provided by the ESMO, NCCN and the present guide-
lines on the duration of chemotherapy and radiotherapy
dose (Table 2). The present recommendations on CNS
prophylaxis are concordant with other author-based,53
and evidence-based recommendations.49 
The present guidelines have some inevitable limits.
They do not account for experimental therapies, such as
thalidomide, and other monoclonal antibodies under
investigation. We are also aware that the potential cost
implications of applying the recommendations have
been only implicitly considered when formulating rec-
ommendations for high-cost drugs or procedures.
However, economic evaluations have supported the
cost-effectiveness of the two main recommendations of
the present guidelines, namely HDT/auto SCT for
relapsed patients,54 and frontline chemoimmunothera-
py.55,56 The present guidelines are expected to improve
adherence to evidence-based practice to promote a
rational use of novel technologies still under evaluation.
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Table 2. Comparison among guidelines for first-line treatment of nodal diffuse large B-cell lymphomas.
BCCA49 NCCN50 ESMO51 ONCOGUIDE52 SIE, SIES, GITMO
Year 2002 2003 2002 2003 2005
Target Malignant NHL DLBCL DLBCL DLBCL DLBCL
Country Canada US Europe Spain Italy
Stage I-II non-bulky CHOP x 3 + IFRT In patients without CHOP21 × > 5 cycles Patients without In patients without adverse
adverse risk factors: + rituximab (CD20+). risk factors risk factors, without mediastinal
CHOP 3-4 cycles ± rituximab Abbreviated (increased β2microglob involvement and with less 
+ locoregional RT (30-40 Gy). chemotherapy and/or B symptoms) and than two sites involved: 
In patients with (+2 cycles after age <60 years: abbreviated chemotherapy with 
adverse risk factors: CR achievement CHOP (or CHOP-like) an anthracycline-containing
CHOP 6-8 cycles ±rituximab recommended for × 3-4 + IFRT (36-40 Gy) regimen plus locoregional RT.
±locoregional RT (30-36 Gy) low-intermediate Patients without Locoregional RT only
risk patients risk factors and in elderly stage I patients
age >60 years: without adverse risk factors
CHOP (or CHOP-like) and with contraindication
× 3-4 ± IFRT to chemotherapy.
Patients with risk factors: Patients with more
treat as stage III-IV than 2 sites involved 
or adverse risk factors:
treat as for stage III-IV disease
Stage I-II bulky CHOP 6-8 cycles ± rituximab Without risk factors: CHOP Treatment as for 
(or CHOP-like)×6-8 ± IFRT (36-40 Gy) or stage III-IV.
With risk factors: treat as stage III-IV
Stage III-IV IPI 0-1 CHOP×6-8 CHOP (preferred to other CHOP (or CHOP-like) 6-8 CHOP, CHOP-like or 
+ rituximab anthracycline-based third-generation
regimens) 6-8 cycles ± rituximab chemotherapy + rituximab 
(to be administered in all the pts >60 yrs).
Stage III-IV IPI >2 Enrollment in a clinical trial CHOP (or CHOP-like) or CHOP, CHOP-like or 
(i.e. SCT) is to be preferred CHOP+ rituximab or clinical trial third-generation 
or CHOP 6-8 cycles ± rituximab chemotherapy + rituximab
Consolidation RT To bulky sites (30-40Gy) Considered for To bulky or residual masses To bulky sites
for stage III-IV disease bulky sites (30-36 Gy) for stage
III-Iv disease and CR or CRu
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